Illumina Closes $7.1B GRAIL Deal Despite Antitrust Challenges.

Citation metadata

Date: Sept-Oct 2021
From: Medical Product Outsourcing(Vol. 19, Issue 7)
Publisher: Rodman Publishing
Document Type: Article
Length: 736 words
Lexile Measure: 1300L

Document controls

Main content

Article Preview :

Illumina Inc. has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.

Illumina first announced its intention to acquire GRAIL nearly a year ago, reuniting illumina with GRAIL four years after it was spun off. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic. Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide.

Regulators in the EU are reviewing the transaction, but a decision is projected after the deal expires. GRAIL has no business in the EU, and the company believes that the European Commission does not have jurisdiction to review the merger as the EU merger thresholds are not met, nor are they met in any EU member state. The General Court of the European Union will hear Illumina's jurisdictional challenge later this year. By holding GRAIL separate while proceedings are ongoing, Illumina is positioned to abide by whatever final decision is reached in these legal processes.

There is no legal impediment to acquiring GRAIL in...

Source Citation

Source Citation   

Gale Document Number: GALE|A677878001